Core Points - The company is implementing the early redemption of the "Hao 24 Convertible Bonds" and will delist them from the Shanghai Stock Exchange starting October 13, 2025 [4][15]. Summary by Sections Redemption Details - The last trading day for the "Hao 24 Convertible Bonds" is September 29, 2025, and the last conversion day is October 10, 2025 [2][3]. - The redemption price is set at 100.1945 CNY per bond, which includes accrued interest [8][10]. - The redemption registration date is October 10, 2025, and the redemption payment date is October 13, 2025 [6][14]. Conditions for Redemption - The company has triggered the conditional redemption clause as the stock price was above 130% of the conversion price for 15 out of 30 trading days from August 25 to September 12, 2025 [5][7]. - The company has the right to redeem all or part of the unconverted bonds if the remaining balance is less than 30 million CNY [7]. Investor Guidance - Investors are advised to convert or sell their bonds within the specified time frame to avoid forced redemption, which could lead to significant investment losses [4][17]. - The current market price of the bonds is significantly higher than the redemption price, indicating potential losses for investors who do not act in time [17].

| 证券代码：603809 | 证券简称：豪能股份 | 公告编号：2025-056 | | --- | --- | --- | | | 转债 | | | 转债代码：113690 | 转债简称：豪 24 | | 成都豪能科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于实施"豪 24 转债"赎回暨摘牌的 重要内容提示： 第一次提示性公告 截至 2025 年 9 月 22 日收市后，距离 9 月 29 日（"豪 24 转债"最后交易日）仅 剩 5 个交易日，9 月 29 日为"豪 24 转债"最后一个交易日。 最后转股日：2025 年 10 月 10 日 截至 2025 年 9 月 22 日收市后，距离 10 月 10 日（"豪 24 转债"最后转股日）仅 剩 8 个交易日，10 月 10 日为"豪 24 转债"最后一个转股日。 成都豪能科技股份有限公司（以下简称"公司"）的股票自 2025 年 8 月 25 日 至 2025 年 9 月 12 日连续三十个交易日内有十五个交易日收盘价格不低于"豪 24 转债" ...

| 证券代码：603809 | 证券简称：豪能股份 公告编号：2025-055 | | --- | --- | | 转债代码：113690 | 转债简称：豪 转债 24 | 成都豪能科技股份有限公司 关于实施"豪 24 转债"赎回暨摘牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 最后转股日：2025 年 10 月 10 日 证券停复牌情况：适用 因提前赎回"豪 24 转债"，本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | | 停复牌类型 | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 113690 | 豪 24 | 转债 | 可转债债券停牌 | 2025/9/30 | | | | 截至 2025 年 9 月 19 日收市后，距离 9 月 29 日（"豪 24 转债"最后交易日）仅 剩 6 个交易日，9 月 29 日为"豪 24 转债"最后一个交易日。 截至 2025 ...

Group 1: Company Overview - Lepu Medical - Lepu Medical is a leading cardiovascular company in China, with a diverse product matrix. In H1 2025, the company achieved revenue of 3.369 billion yuan, a year-on-year decrease of 0.43%, and a net profit of 691 million yuan, down 0.91% year-on-year [3] - The company is strategically expanding into innovative drugs for cardiovascular and metabolic diseases through its subsidiary, Minwei Biotech, which focuses on obesity and type 2 diabetes treatments. As of August 2025, several products are in various clinical trial phases [3] - Lepu Medical is also actively developing its aesthetic medicine segment, with new products like dermal fillers and hyaluronic acid injections receiving approval, indicating strong growth potential in the non-medical insurance market [3] Group 2: Company Overview - Superwin International Holdings - Superwin International Holdings has over 20 years of experience in elastic fabric, with a stable management team. The company generates 55.4% of its revenue from sports fabrics and is well-positioned to capture more orders due to its mature overseas production capacity [6][7] - The company is expected to see net profits of 590 million, 640 million, and 700 million HKD from 2025 to 2027, benefiting from a rebalancing of supply and demand and moderate raw material prices [5][6] - Superwin has maintained a stable dividend payout ratio of around 50%, with a dividend yield exceeding 9% for the past four years, making it an attractive investment opportunity [8] Group 3: Industry Insights - Biopharmaceuticals - The biopharmaceutical industry is witnessing a shift towards innovative drug development, particularly in cardiovascular and metabolic diseases, driven by companies like Lepu Medical [3] - The market for aesthetic medicine is expanding, with increasing regulatory approvals for new products, indicating a growing consumer demand for non-traditional medical treatments [3] Group 4: Industry Insights - Textile and Apparel - The sportswear segment is outpacing other apparel categories, with rising demand for elastic, breathable, and antibacterial fabrics benefiting suppliers like Superwin International [8] - The company is positioned to leverage its established relationships with major sports brands, which have been in collaboration for over five years, ensuring a steady flow of orders [8]

Core Points - The stock of Haoneng Co., Ltd. dropped by 5.33% on September 19, closing at 15.80 CNY per share with a trading volume of 327 million CNY and a turnover rate of 2.36%, resulting in a total market capitalization of 13.586 billion CNY [1] Company Overview - Haoneng Co., Ltd. is located in Chengdu Economic and Technological Development Zone, Sichuan Province, and was established on September 25, 2006, with its listing date on November 28, 2017 [1] - The company's main business involves the research, production, and sales of synchronizer components for automotive transmissions [1] Revenue Composition - The revenue composition of Haoneng Co., Ltd. is as follows: synchronizers account for 48.89%, differentials for 21.21%, other components for 14.50%, aerospace parts for 13.22%, and supplementary items for 2.19% [1] Fund Holdings - Manulife Fund has a significant holding in Haoneng Co., Ltd., with its Manulife Efficient Selection Mixed Fund (LOF) holding 1.6252 million shares, representing 6.42% of the fund's net value, making it the third-largest holding [2] - The fund has reported a floating loss of approximately 1.4464 million CNY as of the latest update [2] Fund Performance - The Manulife Efficient Selection Mixed Fund (LOF) was established on May 12, 2006, with a current size of 387 million CNY, achieving a year-to-date return of 17.64% and a one-year return of 36.65% [2] - Since its inception, the fund has generated a return of 282.07%, with the fund manager, Wu Hua, having a tenure of 11 years and 182 days [2]

Core Points - Chengdu Haoneng Technology Co., Ltd. has approved a bank credit limit application totaling RMB 420 million for 2025, which was authorized by the shareholders' meeting [2] - The company has signed a working capital loan contract with Bank of China Chengdu Jinjing Branch for RMB 50 million with a term of 24 months [3] - The company has cumulative bank credit applications amounting to RMB 3.314 billion, with an unused credit limit of RMB 886 million as of the announcement date [6][7] Credit and Guarantee Details - The company has pledged 100% equity of Chengdu Haoyiqiang Aviation Equipment Manufacturing Co., Ltd. as collateral for the credit, with a maximum guarantee amount of RMB 279.3025 million [4] - The company has also provided guarantees for its subsidiaries, including a maximum liability guarantee of RMB 30 million for Chengdu Haoyiqiang [10] - The total amount of external guarantees provided by the company is RMB 2.332 billion, accounting for 77.11% of the audited net assets for 2024, with no overdue guarantees reported [11] Impact on Company - The credit application is aimed at meeting the daily operational liquidity needs of the company and its subsidiaries, enhancing financial security, and supporting sustainable development [7] - The board of directors believes that the guarantees provided will not harm the interests of the company and its shareholders, and the subsidiaries have stable operations and good credit status [10]

证券日报网讯 9月18日晚间，豪能股份发布公告称，截至本公告披露日，公司对外担保总额为人民币 23.32亿元，占公司2024年度经审计净资产的77.11%，均为对子公司提供的担保，无逾期担保。 （文章来源：证券日报） ...

关于 2025 年度向银行申请授信额度的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 3 月 21 日，成都豪能科技股份有限公司（以下简称"公司"）召开第六 届董事会第十一次会议，审议通过了《关于 2025 年度向银行申请授信额度的议案》， 并经 2025 年 4 月 11 日召开的 2024 年年度股东大会批准，同意公司及子公司向银行 申请总额不超过人民币 420,000.00 万元的授信额度（在不超过总授信额度范围内， 最终以各银行实际审批的授信额度为准）。本次向银行申请授信额度授权期限为公司 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会召开之日止。上述授信 额度仅由公司及子公司使用，授信期限内，授信额度可循环使用。具体内容请详见 2025 年 3 月 22 日刊载于上海证券交易所网站（www.sse.com.cn）及公司指定信息披 露媒体的《关于 2025 年度向银行申请授信额度的公告》（公告编号：2025-013）。 一、本次授信情况概述 | 证券代码：603809 | ...

| 证券代码：603809 | 证券简称：豪能股份 | 公告编号：2025-053 | | --- | --- | --- | | 转债代码：113690 | 转债简称：豪 24 | 转债 | 成都豪能科技股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 本次担保金额 | 3,000.00 | 万元 | 成都昊轶强航空设备制造有限公司 | | --- | --- | --- | --- | --- | | 担保对象 | 实际为其提供的担保余额 | 10,000.00 | | 万元（含本次担保） | | | 是否在前期预计额度内 | ☑是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | ☑否 | □不适用：_________ | 因成都昊轶强航空设备制造有限公司（以下简称"昊轶强"）借款事宜，成 都豪能科技股份有限公司（以下简称"公司"）与成都银行股份有限公司青羊支 行签订了《最高 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][11]. Core Views - The company has shown steady performance in the first half of 2025, with a focus on developing cycloidal reducers and collaborating with various companies in fields such as humanoid robots, robotic dogs, exoskeletons, and dexterous hands [2][11]. - The target price is set at 23.64 CNY, reflecting a 47 times PE ratio for 2025, based on the company's robust earnings forecast [11]. Financial Summary - Total revenue is projected to grow from 1,946 million CNY in 2023 to 4,201 million CNY by 2027, with a compound annual growth rate (CAGR) of approximately 19.2% [4][12]. - Net profit attributable to shareholders is expected to increase from 182 million CNY in 2023 to 669 million CNY in 2027, with significant growth rates, particularly a 76.9% increase in 2024 [4][12]. - Earnings per share (EPS) is forecasted to rise from 0.21 CNY in 2023 to 0.78 CNY in 2027 [4][12]. Market Data - The company's market capitalization is approximately 14,996 million CNY, with a current share price of 17.44 CNY [6][5]. - The stock has shown a 52-week price range of 6.92 CNY to 19.00 CNY, indicating significant volatility and potential for growth [6]. Industry Position - The company is positioned in the transportation equipment and consumer discretionary sectors, with a focus on high-precision planetary and cycloidal reducers [5][11]. - The automotive and aerospace sectors are identified as key growth areas, with ongoing projects with major industry players [11].